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We conducted a retrospective cohort study to compare
Clostridium difficile–associated disease rates determined
by C. difficile–toxin assays and International Classification
of Diseases, 9th Revision (ICD-9) codes. The correlation
between toxin assay results and ICD-9 codes was good (κ
= 0.72, p<0.01). The sensitivity of the ICD-9 codes was
78% and the specificity was 99.7%.
C
lostridium difficile–associated disease (CDAD) is the
most common infectious cause of healthcare-associat-
ed diarrhea (1). Recent studies suggest both the incidence
and severity of CDAD may be increasing (2–9), but no
national surveillance system exists to track CDAD rates.
Some studies have used International Classification of
Diseases, 9th Revision (ICD-9) codes of hospital dis-
charges to study CDAD rates (4,10,11). The validity of this
method has not been studied. We compared CDAD rates
determined by ICD-9 codes to rates determined by C. dif-
ficile–toxin assays at a tertiary-care hospital to determine
the sensitivity and specificity of ICD-9 code–based CDAD
surveillance.
The Study
Data were collected electronically on a retrospective
cohort of patients admitted to Barnes-Jewish Hospital in
Saint Louis from January 1, 2003, through December 31,
2003. Patients who had only 1 admission of <48 hours and
neonates were excluded. Electronic charts were reviewed
for patients who had a positive C. difficile–toxin assay or
the ICD-9 code indicating C. difficile–associated disease
(008.45) (Appendix).
A case of CDAD was defined as a patient with a posi-
tive C. difficile–toxin assay (Tech Laboratory C. difficile
tox A/B II toxin assay [Tech Laboratory, Blacksburg, VA,
USA]) or pseudomembranes seen on colonoscopy.
Because the hospital laboratory performs a C. difficile–
toxin assay only on unformed stool samples and stool toxin
testing is ordered based on clinical suspicion of CDAD, all
patients with a positive toxin assay were considered
CDAD case-patients.
Data were analyzed with SPSS 12.0 for Windows
(SPSS, Inc., Chicago, IL, USA). Statistical analyses
included  κ,  χ2, and Mann-Whitney U tests. A 2-sided
p value of 0.05 was considered significant. This study was
approved by the Washington University Human Studies
Committee.
A total of 45,486 admissions among 28,417 unique
patients were included in the analysis (Figure 1). A C. dif-
ficile–toxin assay was ordered during hospitalization for
3,630 (8%) of these admissions. Toxin assays were posi-
tive (CDTA+) in 662 (18%) admissions. The C. difficile
ICD-9 code was assigned to 745 admissions (ICD9+). The
breakdown of admissions, according to toxin assay and
ICD-9 status, was as follows: 506 had both a positive toxin
assay and received the ICD-9 code (concordant;
CDTA+/ICD9+), 156 had a positive toxin assay but no
ICD-9 code (CDTA+/ICD9–), and 239 received the ICD-9
code but did not have a positive toxin assay
(CDTA–/ICD9+) (Figure 1). The concordance between
toxin assays and ICD-9 codes was good (κ = 0.72, p<0.01).
The overall mean CDAD rate by ICD-9 codes (16.4/1,000
admissions) was significantly higher then the mean rate by
toxin assays (14.6/1,000 admissions) (Figure 2; rate ratio
[RR] 1.13, 95% confidence interval [CI] 1.01–1.25).
The median number of days from admission to stool
collection was greater in admissions with a positive toxin
assay but no ICD-9 code (CDTA+/ICD9–) than in concor-
dant (CDTA+/ICD9+) admissions (6.0 days vs 3.0 days,
p<0.01) (Table 1). The first positive stool sample was col-
lected within 48 hours of discharge for 68 (44%) of admis-
sions with a positive toxin assay only (CDTA+/ICD9–)
admissions, compared with 72 (14%) of concordant
(CDTA+/ICD9+) admissions (p<0.01). 
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Saint Louis, Missouri, USA Figure 1. Flowchart of admission groups. Upon chart review, documentation of a previous histo-
ry of CDAD was evident in 142 (59%) of the ICD-9 code
only (CDTA–/ICD9+) admissions. A C. difficile–toxin
assay had been ordered in 137 (57%) of all ICD-9 code
only (CDTA-/ICD9+) admissions. One-hundred thirty
(54%) had at least 1 stool negative for C. difficile toxin.
Overall, 92% of patients with positive toxin assay
(CDTA+) and 90% of patients with ICD-9 code only
(CDTA–/ICD9+) received antimicrobial drug treatment
for CDAD (Table 2). Metronidazole was prescribed in 187
(78%) of the ICD-9 code only (CDTA–/ICD9+) admis-
sions, compared with 591 (89%) of patients with a positive
toxin assay (CDTA+) (p<0.01). For 75 (31%) of the ICD-
9 code only (CDTA–/ICD9+) admissions, oral van-
comycin was prescribed, compared with 130 (20%) of
patients with a positive toxin assay (CDTA+) (p<0.01).
Thirty-four cases of CDAD were missed by C. diffi-
cile–toxin assay results and subsequently identified
through chart review (3 missed positive toxins, 26 CDAD
patients transferred from other facilities, 3 positive outpa-
tient toxin assays, and 2 diagnosed by colonoscopy), which
brought the total number of cases with positive CDAD
diagnostics to 696. ICD-9 codes correctly identified 540 of
these cases and correctly classified 44,741 admissions as
non-CDAD admissions (sensitivity 78%, specificity
99.7%). When the CDAD rate by toxin assays was adjust-
ed for the additional cases, the adjusted CDAD rate was
15.3/1,000 admissions. This rate was not significantly dif-
ferent from the unadjusted CDAD rate by toxin assay
results (RR 0.95, 95% CI 0.86–1.06) or the rate by ICD-9
codes alone (RR 1.07, 95% CI 0.97–1.19).
Conclusions
Overall, there was good correlation between C. diffi-
cile–toxin assay results and ICD-9 codes. Initially, the
CDAD rate by ICD-9 codes appeared higher than the rate
by toxin assays. However, once the additional CDAD
cases identified through chart review were added, this dif-
ference was not significant.
Admissions with only a positive C. difficile–toxin assay
and no C. difficile ICD-9 code (CDTA+/ICD9–) were more
likely than concordant (CDTA+/ICD9+) admissions to
have their first positive toxin assay within 48 hours of dis-
charge. For these admissions, toxin assay results may not
yet have been back at the time of discharge or CDAD may
not have been considered a primary diagnosis by the physi-
cian and therefore not captured by the medical coders.
Antimicrobial drug treatment patterns suggest ICD-9
code only (CDTA–/ICD9+) admissions were patients who
were more likely to have a history of CDAD.
Metronidazole is first-line therapy for CDAD at our insti-
tution. Oral vancomycin is reserved for recurrent or severe
cases. The observation that more ICD-9 code only
(CDTA–/ICD9+) patients received oral vancomycin indi-
cates that recurrent CDAD may have been suspected in
these patients. In these patients, CDAD appears to have
been diagnosed on the basis of the patient’s history and
symptoms instead of by a positive C. difficile–toxin assay.
This pattern has been previously reported (12).
True CDAD cases may have been misclassified among
the controls. Apatient who did not have a positive C. diffi-
cile–toxin assay, who was not assigned the CDAD ICD-9
code, and whose diagnosis was made by colonoscopy
would have been missed. However, misclassification is
unlikely for two reasons. First, after charts were reviewed,
only 2 additional patients were identified whose diagnosis
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Figure 2. Monthly rates of Clostridium difficile–associated disease
by diagnosis type.was made by colonoscopy alone. Second, the detection of
CDAD cases transferred from other institutions indicates
that CDAD cases diagnosed by methods other than the
toxin assays are being captured by ICD-9 codes.
Use of ICD-9 codes to study CDAD rates has advan-
tages and disadvantages. ICD-9 codes are readily available
from billing databases. In the absence of a national surveil-
lance system for CDAD, ICD-9 codes provide a standard
method for determining CDAD rates that can be used at all
types of hospitals. However, because ICD-9 codes are
assigned at discharge and not on the date of diagnosis,
determining which cases are hospital acquired and which
are community acquired is difficult. Also, ICD-9 codes are
assigned by medical coders, who may not be able to accu-
rately identify a patient’s principal diagnoses as well as a
physician or medical professional. Despite these limita-
tions, ICD-9 codes can likely be used to identify CDAD
cases and track CDAD rates when C. difficile–toxin assay
results are not available.
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Appendix
Details on ICD-9 Codes
The International Classification of Diseases, 9th
Revision, Clinical Modification (ICD-9) code used in this
study was 008.45, “intestinal infection due to Clostridium
difficile,” and is the only ICD-9 code related to CDAD. To
apply this code, medical coders must have documentation
in a patient’s medical record by the treating medical
providers that a patient’s gastroenteritis or colitis is due to
C. difficile. Positive laboratory tests alone are not suffi-
cient to warrant application of the code. At our institution,
ICD-9 coding occurs, on average, 5–7 days after a patient
is discharged from the hospital.
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diagnoses is used throughout the United States. The defini-
tion for the code 008.45 is consistent between hospitals,
although individual coding practices may vary. Although
ICD-9 codes have limitations, they are readily available
from administrative databases and have been used frequent-
ly to identify diagnoses and classify comorbidities (1).
A move to the International Classification of Diseases,
10th Revision, Clinical Modification (ICD-10) system is
anticipated for US hospitals but the exact time of this tran-
sition is not yet known. The ICD-10 system does include a
code for CDAD (A04.7, Enterocolitis due to C. difficile), 
so the ICD-based system presented here could be modified
to be used with the updated coding system.
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